- Home
- SLP vs ABEO Comparison
SLP vs ABEO Comparison
Compare SLP & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLP | ABEO |
|---|---|---|
| Founded | 1996 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 307.5M |
| IPO Year | 1996 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SLP | ABEO |
|---|---|---|
| Price | $16.57 | $5.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $24.00 | $20.00 |
| AVG Volume (30 Days) | 385.1K | ★ 1.1M |
| Earning Date | 04-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | 0.26 | ★ 1.01 |
| Revenue | ★ $59,577,000.00 | $2,998,000.00 |
| Revenue This Year | $3.80 | $1,024.31 |
| Revenue Next Year | $5.90 | $145.42 |
| P/E Ratio | $61.60 | ★ $5.69 |
| Revenue Growth | 10.52 | ★ 258.18 |
| 52 Week Low | $11.09 | $4.00 |
| 52 Week High | $34.01 | $7.54 |
Technical Indicators
Market Signals| Indicator | SLP | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 72.88 | 63.10 |
| Support Level | $16.26 | $5.24 |
| Resistance Level | $19.29 | $7.54 |
| Average True Range (ATR) | 0.86 | 0.26 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 79.56 | 77.51 |
Price Performance
Historical ComparisonAbout SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.